To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy

S M Yin1, D L Li1

  • 1Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.

Cell Stem Cell
|November 8, 2024
PubMed
Abstract

Related Concept Videos